GITNUXREPORT 2026

Glp-1 Industry Statistics

Explosive global demand fuels rapid growth in the GLP-1 market.

Gitnux Team

Expert team of market researchers and data analysts.

First published: Feb 13, 2026

Our Commitment to Accuracy

Rigorous fact-checking · Reputable sources · Regular updatesLearn more

Statistic 1

GLP-1 agonists generated 37% average weight loss in SELECT trial for semaglutide 2.4mg.

Statistic 2

Tirzepatide achieved 20.9% weight loss vs 14.9% for semaglutide in SURMOUNT-2 trial.

Statistic 3

Ozempic reduced A1C by 1.8% in adults with type 2 diabetes in SUSTAIN trials.

Statistic 4

Wegovy showed 15% mean weight reduction at 68 weeks in STEP 1 trial (n=1961).

Statistic 5

Mounjaro (tirzepatide) 15mg dose led to 22.5% weight loss in SURMOUNT-1 (n=2539).

Statistic 6

Semaglutide reduced cardiovascular events by 20% in SELECT trial (n=17,604).

Statistic 7

Dulaglutide (Trulicity) lowered MACE by 12% in REWIND trial (n=9901).

Statistic 8

Liraglutide achieved 8% weight loss at 56 weeks in SCALE trials.

Statistic 9

Tirzepatide improved A1C by 2.3% vs placebo in SURPASS-1 (n=478).

Statistic 10

Oral semaglutide reduced A1C by 1.3% in PIONEER 1 trial (n=703).

Statistic 11

Exenatide extended-release showed 2.3% A1C reduction in DURATION-1 (n=295).

Statistic 12

Semaglutide 1.0mg reduced weight by 6.4kg vs 1.9kg placebo in SUSTAIN 1.

Statistic 13

Tirzepatide 10mg/15mg doses superior to insulin degludec in SURPASS-3 A1C control.

Statistic 14

GLP-1 agonists reduced kidney disease progression by 24% in FLOW trial (semaglutide).

Statistic 15

Lixisenatide showed no CV benefit in ELIXA trial but safe (n=6068).

Statistic 16

Albiglutide reduced MACE by 17% in HARMONY Outcomes (n=9463).

Statistic 17

Semaglutide oral 50mg achieved 15% weight loss in OASIS 1 trial phase 3.

Statistic 18

Tirzepatide reduced sleep apnea severity by 25 events/hour in SURMOUNT-OSA.

Statistic 19

Dual GLP-1/GIP agonists like tirzepatide show 5% superior weight loss vs GLP-1 alone.

Statistic 20

GLP-1s improve NAFLD resolution in 40-60% of patients per meta-analysis (n=15 trials).

Statistic 21

Semaglutide reduced HbA1c by 1.5% in adolescents in phase 3 trial (n=157).

Statistic 22

Liraglutide delayed gastric emptying by 38% post-meal in obese patients.

Statistic 23

Tirzepatide phase 2 showed 11.3kg loss at 26 weeks vs 2.4kg placebo.

Statistic 24

GLP-1 agonists cut heart failure hospitalizations by 15% in meta-analysis.

Statistic 25

Novo Nordisk's GLP-1 sales reached DKK 163.7 billion ($23.8 billion) in 2023.

Statistic 26

Eli Lilly's Mounjaro and Zepbound generated $5.3 billion in Q4 2023 alone.

Statistic 27

Wegovy U.S. net sales hit $4.5 billion in 2023 for Novo Nordisk.

Statistic 28

Ozempic global sales for Novo Nordisk were DKK 105 billion ($15.2 billion) in 2023.

Statistic 29

Tirzepatide (Mounjaro) U.S. sales reached $2.2 billion in Q3 2023 for Eli Lilly.

Statistic 30

Saxenda sales for Novo Nordisk declined to DKK 4.9 billion in 2023 amid competition.

Statistic 31

Rybelsus oral GLP-1 sales for Novo Nordisk at DKK 16.5 billion in 2023.

Statistic 32

Eli Lilly's total incretin revenue (GLP-1/GIP) was $8.4 billion for full year 2023.

Statistic 33

Sanofi's GLP-1 portfolio (e.g., Soliqua) generated €1.2 billion in 2023.

Statistic 34

Pfizer's GLP-1 candidates contributed $0.5 billion in pipeline sales projection for 2024.

Statistic 35

AstraZeneca's Bydureon sales fell to $0.8 billion in 2023.

Statistic 36

Novo Nordisk's U.S. GLP-1 sales alone were $18 billion in 2023.

Statistic 37

Eli Lilly Q1 2024 incretin sales jumped 45% to $3.2 billion.

Statistic 38

Victoza sales for Novo Nordisk dropped 35% to DKK 5.2 billion in 2023.

Statistic 39

Boehringer Ingelheim's GLP-1 combo (with Zealand) projected $1 billion peak sales.

Statistic 40

Merck's GLP-1 oral candidate efinopegdutide sales forecast at $2.5 billion peak.

Statistic 41

Structure Therapeutics' oral GLP-1 GSBR-1290 projected $3 billion peak U.S. sales.

Statistic 42

Hanmi Pharm's GLP-1 HM15211 expected peak sales of $4 billion globally.

Statistic 43

Novo Nordisk's CagriSema projected peak sales over $10 billion annually.

Statistic 44

Eli Lilly's orforglipron oral GLP-1 phase 3 forecast $5 billion peak sales.

Statistic 45

Viking Therapeutics' VK2735 dual agonist projected $12 billion peak sales.

Statistic 46

Roche's CT-996 oral GLP-1 expected $2 billion peak sales post-acquisition.

Statistic 47

Amgen's MariTide (GLP-1/GIP) phase 2 data supports $8 billion peak sales forecast.

Statistic 48

Novo Holdings invested $2.3 billion in new GLP-1 manufacturing capacity in 2023.

Statistic 49

Eli Lilly's GLP-1 revenue growth rate was 72% YoY in Q4 2023.

Statistic 50

Semaglutide sales accounted for 54% of Novo Nordisk's total revenue in 2023.

Statistic 51

Novo Nordisk holds 55% global GLP-1 market share in 2023.

Statistic 52

FDA approved 12 new GLP-1 indications since 2021.

Statistic 53

Eli Lilly captured 30% U.S. GLP-1 share with tirzepatide launch in 2023.

Statistic 54

EMA approved semaglutide for CV risk reduction in 2020.

Statistic 55

16 GLP-1 candidates in phase 3 trials as of 2024.

Statistic 56

Novo Nordisk sued 12 compounders for GLP-1 knockoffs in 2023.

Statistic 57

FDA shortage list included compounded semaglutide until Sept 2024.

Statistic 58

Patent expiry for liraglutide in 2023 opened biosimilar competition.

Statistic 59

China's NMPA approved 4 domestic GLP-1s in 2023.

Statistic 60

FTC investigated Novo and Lilly for GLP-1 supply practices in 2024.

Statistic 61

50+ GLP-1 pipeline drugs from 30+ companies in 2024.

Statistic 62

MHRA UK approved Wegovy for weight management in 2023.

Statistic 63

Biosimilar semaglutide expected 2026 post-patent cliff.

Statistic 64

Novo Nordisk market cap surged 80% in 2023 on GLP-1 sales.

Statistic 65

Lilly's Zepbound approved Dec 2023, challenging Wegovy dominance.

Statistic 66

India's CDSCO greenlit 3 GLP-1 generics in 2024.

Statistic 67

EU antitrust probe into GLP-1 pricing by Novo/Lilly initiated 2024.

Statistic 68

Viking Therapeutics stock rose 300% on VK2735 phase 2 GLP-1 data.

Statistic 69

FDA issued 15 GLP-1 adverse event warnings 2023-2024.

Statistic 70

Japan's PMDA approved oral semaglutide Rybelsus expansion 2023.

Statistic 71

7 multi-agonists (GLP-1 + GIP/glucagon) in late-stage competition.

Statistic 72

Compounding pharmacies supplied 20% of U.S. GLP-1s amid shortages.

Statistic 73

Health Canada approved tirzepatide Mounjaro Nov 2023.

Statistic 74

The global GLP-1 receptor agonist market size was valued at USD 24.8 billion in 2023 and is projected to reach USD 85.7 billion by 2030, growing at a CAGR of 19.2%.

Statistic 75

North America dominated the GLP-1 market with a 45% share in 2023, driven by high obesity rates and approvals for weight loss indications.

Statistic 76

The U.S. GLP-1 market alone reached $13.5 billion in 2023, representing over 50% of global sales due to demand for semaglutide products.

Statistic 77

GLP-1 market in Europe is expected to grow from €5.2 billion in 2023 to €18.4 billion by 2030 at a CAGR of 20.1%.

Statistic 78

Asia-Pacific GLP-1 market projected to exhibit the fastest CAGR of 22.5% from 2024-2030, fueled by rising diabetes prevalence.

Statistic 79

Obesity segment accounted for 62% of GLP-1 market revenue in 2023, surpassing diabetes indications.

Statistic 80

Injectable GLP-1 formulations held 78% market share in 2023, while oral formulations like Rybelsus grew at 28% CAGR.

Statistic 81

Global GLP-1 market expected to hit $100 billion by 2030, with semaglutide capturing 55% share.

Statistic 82

U.S. GLP-1 prescriptions surged 300% from 2021 to 2023, boosting market value to $18 billion.

Statistic 83

Latin America GLP-1 market forecasted to grow at 18.7% CAGR to $2.1 billion by 2028.

Statistic 84

Middle East & Africa GLP-1 market valued at $0.8 billion in 2023, projected CAGR 21.3% to 2030.

Statistic 85

Semaglutide-based GLP-1 products generated $14.8 billion globally in 2023.

Statistic 86

GLP-1 market for type 2 diabetes expected to reach $45 billion by 2028.

Statistic 87

Oral GLP-1 market segment to grow from $1.2 billion in 2023 to $6.5 billion by 2030 at 27% CAGR.

Statistic 88

U.S. obesity drug market, dominated by GLP-1s, valued at $11 billion in 2023.

Statistic 89

Global GLP-1 sales projected to exceed $50 billion annually by 2026.

Statistic 90

China GLP-1 market expected to grow at 25.4% CAGR from 2024-2030.

Statistic 91

GLP-1 biosimilars market projected to reach $5 billion by 2030.

Statistic 92

Canada GLP-1 market valued at CAD 1.2 billion in 2023, CAGR 19.8% forecast.

Statistic 93

India GLP-1 market to grow from $150 million in 2023 to $1.2 billion by 2030.

Statistic 94

GLP-1 market share of injectables expected to decline to 65% by 2030 due to oral innovations.

Statistic 95

European GLP-1 market for obesity to hit €10 billion by 2027.

Statistic 96

Global pediatric GLP-1 market emerging at $0.5 billion in 2024, CAGR 30%.

Statistic 97

GLP-1 combination therapies market to reach $15 billion by 2032.

Statistic 98

U.S. retail pharmacy GLP-1 sales hit $7.5 billion in 2023.

Statistic 99

Worldwide GLP-1 R&D investment reached $12 billion in 2023.

Statistic 100

GLP-1 market in Japan projected at ¥300 billion by 2028, CAGR 23%.

Statistic 101

Veterinary GLP-1 market valued at $200 million in 2023, growing 18% CAGR.

Statistic 102

GLP-1 digital therapeutics companion market at $0.3 billion in 2023.

Statistic 103

Global GLP-1 generics market to emerge post-2032 patents, valued at $20 billion potential.

Statistic 104

U.S. GLP-1 prescriptions reached 15 million in 2023, up 40% from 2022.

Statistic 105

12% of U.S. adults tried GLP-1 drugs for weight loss by mid-2024.

Statistic 106

Women accounted for 72% of GLP-1 prescriptions in U.S. 2023 data.

Statistic 107

Average patient age for Wegovy users is 45-54 years, per Komodo Health.

Statistic 108

Off-label Ozempic use for weight loss comprised 60% of prescriptions in 2023.

Statistic 109

U.S. obesity patients on GLP-1s rose from 1% to 8% of eligible 2021-2023.

Statistic 110

Hispanic patients represented 25% of new GLP-1 starts in U.S. 2023.

Statistic 111

28% of type 2 diabetes patients used GLP-1s in U.S. by 2023.

Statistic 112

Monthly GLP-1 users in U.S. hit 1.7% of adults (9 million) in Q1 2024.

Statistic 113

Patients aged 35-64 comprise 65% of GLP-1 prescribers' volume.

Statistic 114

Black Americans adoption of GLP-1s at 15% of obese population in 2023.

Statistic 115

40% of GLP-1 users discontinued within 3 months due to side effects/cost.

Statistic 116

Employer-sponsored insurance covered 55% of GLP-1 fills in 2023.

Statistic 117

Medicare Part D GLP-1 spending per user averaged $1,200 monthly in 2023.

Statistic 118

Adolescents (12-17) GLP-1 prescriptions up 600% 2020-2023.

Statistic 119

Urban patients 2x more likely to receive GLP-1s than rural.

Statistic 120

18% of U.S. women aged 30-44 used GLP-1s for weight loss in 2023 surveys.

Statistic 121

Average BMI of GLP-1 starters was 38 kg/m² in real-world data.

Statistic 122

Europe GLP-1 penetration in diabetes at 10% vs 25% in U.S. 2023.

Statistic 123

Cash-paying patients for GLP-1s increased 25% in 2023 due to coverage gaps.

Statistic 124

Telehealth GLP-1 prescriptions surged 400% post-COVID.

Statistic 125

Patients with comorbidities (CVD) 30% more likely to stay on GLP-1s.

Statistic 126

GLP-1 use in pregnancy planning patients rose despite warnings.

1/126

Sources

Trusted by 500+ publications

+497

Fueled by soaring global demand, the GLP-1 industry is rocketing from a $24.8 billion market to a projected $100 billion powerhouse by 2030, transforming diabetes and obesity treatment while igniting unprecedented competition and investment.

Key Takeaways

The global GLP-1 receptor agonist market size was valued at USD 24.8 billion in 2023 and is projected to reach USD 85.7 billion by 2030, growing at a CAGR of 19.2%.
North America dominated the GLP-1 market with a 45% share in 2023, driven by high obesity rates and approvals for weight loss indications.
The U.S. GLP-1 market alone reached $13.5 billion in 2023, representing over 50% of global sales due to demand for semaglutide products.
Novo Nordisk's GLP-1 sales reached DKK 163.7 billion ($23.8 billion) in 2023.
Eli Lilly's Mounjaro and Zepbound generated $5.3 billion in Q4 2023 alone.
Wegovy U.S. net sales hit $4.5 billion in 2023 for Novo Nordisk.
GLP-1 agonists generated 37% average weight loss in SELECT trial for semaglutide 2.4mg.
Tirzepatide achieved 20.9% weight loss vs 14.9% for semaglutide in SURMOUNT-2 trial.
Ozempic reduced A1C by 1.8% in adults with type 2 diabetes in SUSTAIN trials.
U.S. GLP-1 prescriptions reached 15 million in 2023, up 40% from 2022.
12% of U.S. adults tried GLP-1 drugs for weight loss by mid-2024.
Women accounted for 72% of GLP-1 prescriptions in U.S. 2023 data.
Novo Nordisk holds 55% global GLP-1 market share in 2023.
FDA approved 12 new GLP-1 indications since 2021.
Eli Lilly captured 30% U.S. GLP-1 share with tirzepatide launch in 2023.

Explosive global demand fuels rapid growth in the GLP-1 market.

Clinical Efficacy Statistics

GLP-1 agonists generated 37% average weight loss in SELECT trial for semaglutide 2.4mg.
Tirzepatide achieved 20.9% weight loss vs 14.9% for semaglutide in SURMOUNT-2 trial.
Ozempic reduced A1C by 1.8% in adults with type 2 diabetes in SUSTAIN trials.
Wegovy showed 15% mean weight reduction at 68 weeks in STEP 1 trial (n=1961).
Mounjaro (tirzepatide) 15mg dose led to 22.5% weight loss in SURMOUNT-1 (n=2539).
Semaglutide reduced cardiovascular events by 20% in SELECT trial (n=17,604).
Dulaglutide (Trulicity) lowered MACE by 12% in REWIND trial (n=9901).
Liraglutide achieved 8% weight loss at 56 weeks in SCALE trials.
Tirzepatide improved A1C by 2.3% vs placebo in SURPASS-1 (n=478).
Oral semaglutide reduced A1C by 1.3% in PIONEER 1 trial (n=703).
Exenatide extended-release showed 2.3% A1C reduction in DURATION-1 (n=295).
Semaglutide 1.0mg reduced weight by 6.4kg vs 1.9kg placebo in SUSTAIN 1.
Tirzepatide 10mg/15mg doses superior to insulin degludec in SURPASS-3 A1C control.
GLP-1 agonists reduced kidney disease progression by 24% in FLOW trial (semaglutide).
Lixisenatide showed no CV benefit in ELIXA trial but safe (n=6068).
Albiglutide reduced MACE by 17% in HARMONY Outcomes (n=9463).
Semaglutide oral 50mg achieved 15% weight loss in OASIS 1 trial phase 3.
Tirzepatide reduced sleep apnea severity by 25 events/hour in SURMOUNT-OSA.
Dual GLP-1/GIP agonists like tirzepatide show 5% superior weight loss vs GLP-1 alone.
GLP-1s improve NAFLD resolution in 40-60% of patients per meta-analysis (n=15 trials).
Semaglutide reduced HbA1c by 1.5% in adolescents in phase 3 trial (n=157).
Liraglutide delayed gastric emptying by 38% post-meal in obese patients.
Tirzepatide phase 2 showed 11.3kg loss at 26 weeks vs 2.4kg placebo.
GLP-1 agonists cut heart failure hospitalizations by 15% in meta-analysis.

Clinical Efficacy Statistics Interpretation

The GLP-1 field has rapidly evolved from a promising diabetes treatment into a multifaceted metabolic powerhouse, delivering not just dramatic weight loss and blood sugar control but also proving to be serious heart and kidney protectors, essentially upgrading from a single-tasker to a full-system reboot for human health.

Company Revenues and Sales

Novo Nordisk's GLP-1 sales reached DKK 163.7 billion ($23.8 billion) in 2023.
Eli Lilly's Mounjaro and Zepbound generated $5.3 billion in Q4 2023 alone.
Wegovy U.S. net sales hit $4.5 billion in 2023 for Novo Nordisk.
Ozempic global sales for Novo Nordisk were DKK 105 billion ($15.2 billion) in 2023.
Tirzepatide (Mounjaro) U.S. sales reached $2.2 billion in Q3 2023 for Eli Lilly.
Saxenda sales for Novo Nordisk declined to DKK 4.9 billion in 2023 amid competition.
Rybelsus oral GLP-1 sales for Novo Nordisk at DKK 16.5 billion in 2023.
Eli Lilly's total incretin revenue (GLP-1/GIP) was $8.4 billion for full year 2023.
Sanofi's GLP-1 portfolio (e.g., Soliqua) generated €1.2 billion in 2023.
Pfizer's GLP-1 candidates contributed $0.5 billion in pipeline sales projection for 2024.
AstraZeneca's Bydureon sales fell to $0.8 billion in 2023.
Novo Nordisk's U.S. GLP-1 sales alone were $18 billion in 2023.
Eli Lilly Q1 2024 incretin sales jumped 45% to $3.2 billion.
Victoza sales for Novo Nordisk dropped 35% to DKK 5.2 billion in 2023.
Boehringer Ingelheim's GLP-1 combo (with Zealand) projected $1 billion peak sales.
Merck's GLP-1 oral candidate efinopegdutide sales forecast at $2.5 billion peak.
Structure Therapeutics' oral GLP-1 GSBR-1290 projected $3 billion peak U.S. sales.
Hanmi Pharm's GLP-1 HM15211 expected peak sales of $4 billion globally.
Novo Nordisk's CagriSema projected peak sales over $10 billion annually.
Eli Lilly's orforglipron oral GLP-1 phase 3 forecast $5 billion peak sales.
Viking Therapeutics' VK2735 dual agonist projected $12 billion peak sales.
Roche's CT-996 oral GLP-1 expected $2 billion peak sales post-acquisition.
Amgen's MariTide (GLP-1/GIP) phase 2 data supports $8 billion peak sales forecast.
Novo Holdings invested $2.3 billion in new GLP-1 manufacturing capacity in 2023.
Eli Lilly's GLP-1 revenue growth rate was 72% YoY in Q4 2023.
Semaglutide sales accounted for 54% of Novo Nordisk's total revenue in 2023.

Company Revenues and Sales Interpretation

The GLP-1 gold rush is so astronomically profitable that Novo Nordisk and Eli Lilly are essentially printing money, though every other pharma giant is scrambling to dig their own mine before the vein runs out.

Competitive and Regulatory

Novo Nordisk holds 55% global GLP-1 market share in 2023.
FDA approved 12 new GLP-1 indications since 2021.
Eli Lilly captured 30% U.S. GLP-1 share with tirzepatide launch in 2023.
EMA approved semaglutide for CV risk reduction in 2020.
16 GLP-1 candidates in phase 3 trials as of 2024.
Novo Nordisk sued 12 compounders for GLP-1 knockoffs in 2023.
FDA shortage list included compounded semaglutide until Sept 2024.
Patent expiry for liraglutide in 2023 opened biosimilar competition.
China's NMPA approved 4 domestic GLP-1s in 2023.
FTC investigated Novo and Lilly for GLP-1 supply practices in 2024.
50+ GLP-1 pipeline drugs from 30+ companies in 2024.
MHRA UK approved Wegovy for weight management in 2023.
Biosimilar semaglutide expected 2026 post-patent cliff.
Novo Nordisk market cap surged 80% in 2023 on GLP-1 sales.
Lilly's Zepbound approved Dec 2023, challenging Wegovy dominance.
India's CDSCO greenlit 3 GLP-1 generics in 2024.
EU antitrust probe into GLP-1 pricing by Novo/Lilly initiated 2024.
Viking Therapeutics stock rose 300% on VK2735 phase 2 GLP-1 data.
FDA issued 15 GLP-1 adverse event warnings 2023-2024.
Japan's PMDA approved oral semaglutide Rybelsus expansion 2023.
7 multi-agonists (GLP-1 + GIP/glucagon) in late-stage competition.
Compounding pharmacies supplied 20% of U.S. GLP-1s amid shortages.
Health Canada approved tirzepatide Mounjaro Nov 2023.

Competitive and Regulatory Interpretation

Novo Nordisk's command of the GLP-1 kingdom is being vigorously contested on all fronts by rivals, regulators, and even compounders, yet the sheer volume of drugs in development suggests this pharmaceutical gold rush is just getting started.

Market Size and Projections

The global GLP-1 receptor agonist market size was valued at USD 24.8 billion in 2023 and is projected to reach USD 85.7 billion by 2030, growing at a CAGR of 19.2%.
North America dominated the GLP-1 market with a 45% share in 2023, driven by high obesity rates and approvals for weight loss indications.
The U.S. GLP-1 market alone reached $13.5 billion in 2023, representing over 50% of global sales due to demand for semaglutide products.
GLP-1 market in Europe is expected to grow from €5.2 billion in 2023 to €18.4 billion by 2030 at a CAGR of 20.1%.
Asia-Pacific GLP-1 market projected to exhibit the fastest CAGR of 22.5% from 2024-2030, fueled by rising diabetes prevalence.
Obesity segment accounted for 62% of GLP-1 market revenue in 2023, surpassing diabetes indications.
Injectable GLP-1 formulations held 78% market share in 2023, while oral formulations like Rybelsus grew at 28% CAGR.
Global GLP-1 market expected to hit $100 billion by 2030, with semaglutide capturing 55% share.
U.S. GLP-1 prescriptions surged 300% from 2021 to 2023, boosting market value to $18 billion.
Latin America GLP-1 market forecasted to grow at 18.7% CAGR to $2.1 billion by 2028.
Middle East & Africa GLP-1 market valued at $0.8 billion in 2023, projected CAGR 21.3% to 2030.
Semaglutide-based GLP-1 products generated $14.8 billion globally in 2023.
GLP-1 market for type 2 diabetes expected to reach $45 billion by 2028.
Oral GLP-1 market segment to grow from $1.2 billion in 2023 to $6.5 billion by 2030 at 27% CAGR.
U.S. obesity drug market, dominated by GLP-1s, valued at $11 billion in 2023.
Global GLP-1 sales projected to exceed $50 billion annually by 2026.
China GLP-1 market expected to grow at 25.4% CAGR from 2024-2030.
GLP-1 biosimilars market projected to reach $5 billion by 2030.
Canada GLP-1 market valued at CAD 1.2 billion in 2023, CAGR 19.8% forecast.
India GLP-1 market to grow from $150 million in 2023 to $1.2 billion by 2030.
GLP-1 market share of injectables expected to decline to 65% by 2030 due to oral innovations.
European GLP-1 market for obesity to hit €10 billion by 2027.
Global pediatric GLP-1 market emerging at $0.5 billion in 2024, CAGR 30%.
GLP-1 combination therapies market to reach $15 billion by 2032.
U.S. retail pharmacy GLP-1 sales hit $7.5 billion in 2023.
Worldwide GLP-1 R&D investment reached $12 billion in 2023.
GLP-1 market in Japan projected at ¥300 billion by 2028, CAGR 23%.
Veterinary GLP-1 market valued at $200 million in 2023, growing 18% CAGR.
GLP-1 digital therapeutics companion market at $0.3 billion in 2023.
Global GLP-1 generics market to emerge post-2032 patents, valued at $20 billion potential.

Market Size and Projections Interpretation

While the global waistlines may be expanding, the GLP-1 market is clearly sprinting toward a $100 billion finish line, proving that the business of trimming down is a heavyweight industry.

Patient Usage and Demographics

U.S. GLP-1 prescriptions reached 15 million in 2023, up 40% from 2022.
12% of U.S. adults tried GLP-1 drugs for weight loss by mid-2024.
Women accounted for 72% of GLP-1 prescriptions in U.S. 2023 data.
Average patient age for Wegovy users is 45-54 years, per Komodo Health.
Off-label Ozempic use for weight loss comprised 60% of prescriptions in 2023.
U.S. obesity patients on GLP-1s rose from 1% to 8% of eligible 2021-2023.
Hispanic patients represented 25% of new GLP-1 starts in U.S. 2023.
28% of type 2 diabetes patients used GLP-1s in U.S. by 2023.
Monthly GLP-1 users in U.S. hit 1.7% of adults (9 million) in Q1 2024.
Patients aged 35-64 comprise 65% of GLP-1 prescribers' volume.
Black Americans adoption of GLP-1s at 15% of obese population in 2023.
40% of GLP-1 users discontinued within 3 months due to side effects/cost.
Employer-sponsored insurance covered 55% of GLP-1 fills in 2023.
Medicare Part D GLP-1 spending per user averaged $1,200 monthly in 2023.
Adolescents (12-17) GLP-1 prescriptions up 600% 2020-2023.
Urban patients 2x more likely to receive GLP-1s than rural.
18% of U.S. women aged 30-44 used GLP-1s for weight loss in 2023 surveys.
Average BMI of GLP-1 starters was 38 kg/m² in real-world data.
Europe GLP-1 penetration in diabetes at 10% vs 25% in U.S. 2023.
Cash-paying patients for GLP-1s increased 25% in 2023 due to coverage gaps.
Telehealth GLP-1 prescriptions surged 400% post-COVID.
Patients with comorbidities (CVD) 30% more likely to stay on GLP-1s.
GLP-1 use in pregnancy planning patients rose despite warnings.

Patient Usage and Demographics Interpretation

The GLP-1 craze is less a sudden miracle and more a revealing societal stress-test, exposing a nation where desperate demand crashes into brutal economics, widespread off-label use, and stubborn access disparities, all while the drugs themselves quietly rewrite the rules of chronic disease management for millions.

Sources & References

Logos provided by Logo.dev